Ayodeji Adegunsoye

List of Publications by Year
in descending order

68	2,218	201575 27	243529 44
papers	citations	h-index	g-index

71	71	71	2248
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterisation of patients with interstitial pneumonia with autoimmune features. European Respiratory Journal, 2016, 47, 1767-1775.	3.1	219
2	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
3	Telomere length and genetic variant associations with interstitial lung disease progression and survival. European Respiratory Journal, 2019, 53, 1801641.	3.1	119
4	CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Diseaseâ€“Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. American Journal of Roentgenology, 2018, 210, 307-313.	1.0	98
5	Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Annals of the American Thoracic Society, 2019, 16, 580-588.	1.5	93
6	Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respiratory Medicine, 2016, 121, 117-122.	1.3	85
7	Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Research, 2017, 3, 00016-2017.	1.1	84
8	Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1154-1163.	2.5	81
9	Comprehensive Care of the Lung Transplant Patient. Chest, 2017, 152, 150-164.	0.4	74
10	CT Findings, Radiologic-Pathologic Correlation, and Imaging Predictors of Survival for Patients With Interstitial Pneumonia With Autoimmune Features. American Journal of Roentgenology, 2017, 208, 1229-1236.	1.0	47
11	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	6.3	47
12	Prevalence and Clinical Significance ofÂAntineutrophil Cytoplasmic Antibodies inÂNorth American Patients With Idiopathic Pulmonary Fibrosis. Chest, 2019, 156, 715-723.	0.4	45
13	Association of Black Race with Outcomes in COVID-19 Disease: A Retrospective Cohort Study. Annals of the American Thoracic Society, 2020, 17, 1336-1339.	1.5	44
14	Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features. Respiratory Medicine, 2016, 114, 53-60.	1.3	42
15	CT findings associated with survival in chronic hypersensitivity pneumonitis. European Radiology, 2017, 27, 5127-5135.	2.3	41
16	Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort. Chest, 2018, 153, 349-360.	0.4	40
17	Lung function trajectory in progressive fibrosing interstitial lung disease. European Respiratory Journal, 2022, 59, 2101396.	3.1	40
18	Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, 150, 1371-1386.	0.4	39

#	Article	IF	Citations
19	African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis. European Respiratory Journal, 2018, 51, 1800255.	3.1	37
20	Integrating Genomics Into Management ofÂFibrotic Interstitial Lung Disease. Chest, 2019, 155, 1026-1040.	0.4	37
21	Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 747-759.	2.5	36
22	Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respiratory Research, 2019, 20, 253.	1.4	35
23	Imaging of Hypersensitivity Pneumonitis. Radiologic Clinics of North America, 2016, 54, 1033-1046.	0.9	34
24	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2021, 57, 2002872.	3.1	32
25	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 1526-1534.	0.4	31
26	Underreporting of Interstitial Lung Abnormalities on Lung Cancer Screening Computed Tomography. Annals of the American Thoracic Society, 2018, 15, 764-766.	1.5	30
27	Circulating Plasma Biomarkers of Progressive Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 250-253.	2.5	30
28	Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Frontiers in Immunology, 2016, 7, 516.	2.2	29
29	Interstitial Pneumonia With Autoimmune Features: Value of Histopathology. Archives of Pathology and Laboratory Medicine, 2017, 141, 960-969.	1.2	29
30	Etiopathogenetic Mechanisms of Pulmonary Hypertension in Sleep-Related Breathing Disorders. Pulmonary Medicine, 2012, 2012, 1-10.	0.5	27
31	Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea. Mediators of Inflammation, 2015, 2015, 1-13.	1.4	27
32	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208.	2.5	27
33	CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. American Journal of Roentgenology, 2018, 210, 1034-1041.	1.0	26
34	Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. European Respiratory Journal, 2020, 56, 2001205.	3.1	24
35	ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunology, 2018, 11, 61-70.	2.7	23
36	Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Advances, 2020, 4, 4873-4886.	2.5	23

#	Article	IF	Citations
37	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest, 2020, 158, 1701-1712.	0.4	19
38	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
39	Characteristics and Prevalence of Domestic and Occupational Inhalational Exposures Across Interstitial Lung Diseases. Chest, 2021, 160, 209-218.	0.4	18
40	Echocardiographic Evaluation of Calcific Aortic Stenosis in the Older Adult. Echocardiography, 2011, 28, 117-129.	0.3	16
41	Automated CT Analysis of Major Forms of Interstitial Lung Disease. Journal of Clinical Medicine, 2020, 9, 3776.	1.0	14
42	De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. Chest, 2017, 152, 683-685.	0.4	12
43	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	1.3	12
44	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
45	Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis. Frontiers in Medicine, 2017, 4, 170.	1.2	10
46	Vessel-related structures predict UIP pathology in those with a non-IPF pattern on CT. European Radiology, 2021, 31, 7295-7302.	2.3	10
47	A series of <scp>COVID</scp>â€19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza. Journal of Pathology: Clinical Research, 2021, 7, 459-470.	1.3	9
48	A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria. European Respiratory Journal, 2016, 48, 1813-1814.	3.1	8
49	Hospitalizations in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 257.	1.4	8
50	High-titer rheumatoid factor seropositivity predicts mediastinal lymphadenopathy and mortality in rheumatoid arthritis-related interstitial lung disease. Scientific Reports, 2021, 11, 22821.	1.6	8
51	Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatology Advances in Practice, 2021, 5, ii1-ii9.	0.3	7
52	A 20-year-old woman with rapidly progressive dyspnea and diffuse pulmonary infiltrates. Respiratory Medicine Case Reports, 2012, 5, 34-36.	0.2	6
53	The role of echocardiography in the evaluation and management of aortic stenosis in the older adult. International Journal of Cardiology, 2012, 155, 39-48.	0.8	6
54	Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. Clinics in Chest Medicine, 2021, 42, 251-261.	0.8	6

#	Article	IF	Citations
55	Interstitial Lung Disease in Firefighters: An Emerging Occupational Hazard. Frontiers in Medicine, 2022, 9, 864658.	1.2	6
56	Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. BioMed Research International, 2015, 2015, 1-16.	0.9	5
57	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulmonary Medicine, 2018, 18, 30.	0.8	5
58	Racial Disparities in Pulmonary Fibrosis and the Impact on the Black Population. Archivos De Bronconeumologia, 2022, 58, 590-592.	0.4	5
59	The Progression to Interstitial Lung Disease. Chest, 2021, 160, 400-402.	0.4	4
60	Inhaled Nitric Oxide for Fibrotic Interstitial Lung Disease: A Step Forward. Annals of the American Thoracic Society, 2022, 19, 536-538.	1.5	4
61	Diagnostic Delay in Idiopathic Pulmonary Fibrosis: Where the Rubber Meets the Road. Annals of the American Thoracic Society, 2019, 16, 310-312.	1.5	2
62	MUC5B promoter variant: genomic fingerprint for early identification of undiagnosed pulmonary fibrosis. Thorax, 2019, 74, 1111-1112.	2.7	2
63	Anti-RNA binding protein positivity in idiopathic interstitial pneumonia. Respiratory Medicine, 2019, 146, 23-27.	1.3	1
64	Molecular pathways in idiopathic pulmonary fibrosis pathogenesis: Transcending barriers to optimally targeted pharmacotherapies. EBioMedicine, 2021, 67, 103373.	2.7	1
65	Risk, Race, and Structural Racism. Annals of the American Thoracic Society, 2021, 18, 1289-1290.	1.5	1
66	Reply to Lescoat et al. and to Khamis et al.. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1041-1042.	2.5	0
67	Anticoagulation and Pulmonary Fibrosis. Chest, 2021, 159, 1321-1323.	0.4	0
68	Association of antinuclear antibody seropositivity with inhaled environmental exposures in patients with interstitial lung disease. ERJ Open Research, 2021, 7, 00254-2021.	1.1	0